A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
No Thumbnail Available
Identifiers
Date
2019-10-01
Authors
Krebs, M.
Brunsvig, P.
Helland, A.
Vinolas, N.
Aix, S.
Carcereny, E.
Domine Gomez, M.
Trigo Perez, J. M.
Arriola, E.
Garcia Campelo, R.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
bemcentinib, AXL, Pembrolizumab